European Union health authorities have long promoted a research agenda that claims to be inclusive, yet recent analysis reveals that the standard model of the human body remains overwhelmingly male. The disparity shows up in drug trials, funding allocations and the diagnosis of conditions that predominantly affect women.

In the EU, 72 percent of clinical studies still fail to publish results broken down by sex or gender. Pregnant women are almost entirely absent: less than four in a thousand trials include them, and a mere one in a thousand enrols breastfeeding participants. The numbers are stark, but they mask a deeper problem, the way medical knowledge has been constructed over decades.

Research design still favours the male body

Historically, researchers have justified the exclusion of women by pointing to hormonal cycles and the ethical complexities of pregnancy. A male body, they argued, offered a "cleaner" experimental platform, free from the fluctuations that could confound results. That convenience, however, has left a permanent blind spot in the evidence base that doctors rely on for diagnosis, dosing and treatment guidelines.

When the underlying data are incomplete, the gaps travel through the entire health system. Diagnostic criteria are drafted on male‑centric studies, drug dosages are calibrated for men, and clinical guidelines echo those choices. The result is a cascade of mis‑diagnoses and sub‑optimal therapies for half the population.

Consequences for women's health

Cardiovascular disease illustrates the cost. It is the leading cause of death among women in the EU, yet women are twice as likely as men to have heart failure misdiagnosed because their symptoms are labelled "atypical". The term itself presupposes a male norm.

Endometriosis, a painful condition affecting an estimated 10‑15 percent of women of reproductive age, often takes six to ten years to be correctly identified. The delay stems from a research record that barely touches the disease: out of almost 146,000 EU‑funded projects over four decades, only ten have focused specifically on endometriosis.

Menopause, which impacts 85 percent of women, suffers a similar neglect. While research funding has concentrated on the fertile years, perimenopause and post‑menopausal health receive far less attention, despite the profound impact on quality of life and long‑term disease risk.

Funding patterns reinforce the bias

In 2020, women's health research attracted just five percent of global research and development spending. The World Economic Forum estimates that closing the investment gap could add €860 billion to the global economy each year by 2040, a figure that underscores both the social and economic stakes.

Funding choices shape what is studied, which in turn determines what is understood. When conditions that predominantly affect women are under‑funded, the medical community lacks the data needed to develop accurate diagnostics and effective treatments. This creates a feedback loop: poor evidence leads to poor outcomes, which then justify continued under‑investment.

Calls for systemic change

Health advocates argue that the solution must begin at the earliest stages of research. Sex‑ and gender‑based analysis should be a mandatory component of every EU‑funded project, and data sets must be disaggregated by sex to allow meaningful comparison.

European policymakers have the tools to enforce such standards. The EU's Horizon Europe programme already includes provisions for gender‑balanced research, but implementation remains uneven. Critics say that without strict monitoring and dedicated funding streams for women‑focused studies, the male default will persist.

Medical education also needs reform. Training programmes should teach future doctors to recognise that diseases can present differently in women, and to question diagnostic algorithms that were built on male‑centric data.

Broader implications for Europe

Beyond the immediate health impact, the gender bias in research threatens Europe's ambition to be a global leader in biotechnology and pharmaceuticals. Companies that develop drugs based on incomplete data risk costly post‑market failures and legal challenges, while competitors that invest in gender‑inclusive trials could capture new markets.

Moreover, the issue intersects with reproductive rights. Access to safe, legal abortion remains a contentious political topic across the continent, and the lack of robust research on women's reproductive health hampers evidence‑based policy making.

Public pressure is mounting. A petition signed by one million Europeans recently called on Brussels to allocate dedicated funds for safe abortion services, highlighting how health policy, gender equity and human rights are intertwined.

What comes next?

Experts suggest a three‑pronged approach: first, enforce mandatory sex‑disaggregated reporting for all clinical trials; second, earmark a larger share of research budgets for conditions that disproportionately affect women; third, revise medical curricula to embed gender‑sensitive diagnostics.

If Europe can align its research funding with the demographic reality that women constitute half of the population, the continent stands to gain both in health outcomes and economic growth. The challenge now is to translate the rhetoric of inclusion into concrete, enforceable policies that reshape the evidence base from the laboratory to the bedside.

Only then will the medical science that Europe prides itself on truly serve all its citizens, rather than perpetuating a legacy built on a single gender's physiology.